Better Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics.
San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more.
Better Therapeutics’ platform aims to address the cognitive patterns that drive eating habits and other behavioral factors associated with such diseases.
The company reported the outcomes of three studies, including the first study of nutritional cognitive behavioral therapy (nCBT) as a potential treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), according to a news release.
In collaboration with Arizona Liver Health, the company has commenced the LivVita study for evaluating the feasibility of nCBT in reducing liver fat and improving liver disease biomarkers in NAFLD and NASH. The study recently enrolled its first patients.
Additionally, the company expanded its real-world evidence study of BT-001 to include Mass General Brigham. That study has begun enrolling patients with type 2 diabetes as it aims to demonstrate statistically significant and clinically meaningful reductions in the A1c measure of blood sugar. Recent primary endpoint data demonstrated such reduction, the company said.
Finally, the company announced that the Durham Veterans Administration Medical Center joined the real-world evidence study for BT-001 held in collaboration with the Colorado Prevention Center.
“Demonstrating the potential to improve and maintain glycemic control and reduce ongoing healthcare costs and medications within the veteran community is of critical importance,” Better Therapeutics CMO Dr. Mark Berman said in the release. “Veterans suffer disproportionately from type 2 diabetes, which is the largest driver of costs within the VA.”
